The association of Interleukin-6 polymorphism (rs1800795) with microvascular complications in type 2 diabetes mellitus

Jieyuan Cui¹,²*, Xiaolin Zhang³, Cheng Guo², Lin Zhang²*

1. Department of Nephrology and Immunology, Children’s Hospital of Hebei Province, Shijiazhuang, China 050031
2. Department of Pediatric, The Third Hospital of Hebei Medical University, Shijiazhuang, China 050051

* Corresponding author: 1. Jueyuan Cui, E-mail: cuijueyuan_0@126.com; 2. Lin Zhang, E-mail: lzhang79@126.com

Author contributions: Jieyuan Cui and Cheng Guo reviewed the literature, and wrote the paper; Xiaolin Zhang designed the meta-analysis; Lin Zhang revised the paper; all authors have read and approved the final version of this manuscript.
Abstract

Objectives: To evaluate the effects of the single nucleotide polymorphism (SNP) rs1800795 in Interleukin-6 (IL-6) gene on diabetic microvascular complications of type 2 diabetes mellitus (T2DM), using statistical meta-analysis.

Methods: Literature pertaining to the relationship between the SNP rs1800795 and microvascular complications of T2DM including diabetic retinopathy, diabetic nephropathy, diabetic neuropathy and foot disease, was retrieved from PubMed, Web of Science Knowledge and SinoMed databases. Original information was analyzed using Stata 12.0, including meta-analysis statistics, test for heterogeneity, evaluation of publication bias and sensitivity. Subgroup analysis was conducted to assess the effect of specific factors on the corresponding results.

Results: In total, 14 eligible articles were obtained. The SNP rs1800795 in IL-6 gene is not correlated with risk of microvascular complications in T2DM. Among the original literature, a genetic model (OR=1.071, 95% CI: 0.681-1.685, P=0.767), an allelic genetic model (OR=1.010, 95% CI: 0.959-1.063, P=0.703), a heterozygote genetic model (OR=1.107, 95% CI: 0.916-1.339, P=0.292), a dominant genetic model (OR=1.108, 95% CI: 0.885-1.387, P=0.372), and a recessive genetic model (OR=0.978, 95% CI: 0.646-1.478, P=0.917) were included respectively. In the subgroup analysis by types of diabetic microvascular complications, we found no correlation between the SNP rs1000795 polymorphism and complications of T2DM in either the homozygote genetic model or the allelic genetic model (P<0.05).

Conclusion: Our results demonstrate that rs1800795 polymorphism in IL-6 gene is not correlated with the susceptibility of microvascular complications of T2DM.

Key words: Gene polymorphism; rs1800795; Interleukin-6 gene; Type 2 diabetes mellitus; Diabetic microvascular complications

1. Introduction

Diabetes mellitus (DM) is a chronic metabolic disease. Over 382 million people worldwide have DM, the prevalence of type 2 diabetes mellitus (T2DM) in children and adolescents is on the rising around the world, in parallel with the increase in the rate of obesity [1]. DM might become the 7th leading cause of death in humans by 2030 [2]. DM is
associated with microvascular and macrovascular complications, which are considered one of
the major causes of morbidity and mortality. Chronic complications, especially microvascular
complications (diabetic retinopathy, nephropathy, foot disease and neuropathy) are the major
dangerous outcome of this disease. Chronic inflammatory processes are involved in the
development of diabetic microvascular complications. Inflammatory cytokines including
interleukin-6 (IL-6) play an important role in the pathogenesis of T2DM and its complications
[3].

The single nucleotide polymorphism (SNP) of IL-6 gene has attracted more and more
attention recently. Significant sequence variation of IL-6 174G/C gene is widely distributed at
varying serum IL-6 levels in genetically susceptible individuals [4]. G/C polymorphism at the
position-174 in IL-6 promoter region (rs1800795) has been found to correlate with
retinopathy, nephropathy [5], increased albumin-to-creatinine ratio as well as poor glycemic
control and hyperlipidemia in type 1 diabetes mellitus (T1DM) [6]. However, the results of
current studies on the involvement of this SNP rs1800795 in diabetic complications in T2DM
are controversial. Whether IL-6 gene polymorphisms rs1800795 may serve as genetic
predictors for the progression of complications in T2DM, and contribute to the identification
of patients with high risk of diabetic complications, thus helping them with tailored
treatments remains unclear. We conducted firstly a meta-analysis of eligible case-control
studies of SNP rs1800795 and the risk of diabetic microvascular complications in T2DM to
assess the questions raised above.

2. Materials and methods

2.1. Retrieval strategy
We intended to summarize data on the correlation between SNP rs1800795 (174G/C) in
IL-6 gene and the risk of microvascular complications including diabetic retinopathy,
nephropathy, neuropathy or foot disease in T2DM. In this field, we conducted a literature
search in PubMed, Web of Science Knowledge and SinoMed databases for related studies
from January 1, 2000 to December 1, 2019. The search terms used are: (1) ‘SNP’ OR ‘single
gene polymorphism’ OR ‘mutation’; (2) ‘rs1800795’ OR ‘Interieukin-6’ OR ‘IL-6 174G/C’;
(3) ‘type 2 diabetes’ OR ‘type 2 diabetes mellitus’ OR ‘T2DM’; (4) ‘diabetic retinopathy’ OR
‘diabetic nephropathy’ OR ‘diabetic neuropathy’ OR ‘diabetic foot disease’ OR ‘diabetic
complications’ OR ‘diabetic microvascular complications’. We made an effort to contact
authors if some relevant data were needed. We have also done a bibliographic search for any
other relevant studies.

This meta-analysis was undertaken in accordance with PRISMA guidelines (http://prisma-statement.org/PRISMAStatement/Checklist).

2.2. Inclusion criteria

For inclusion, all data were used as measurement data in our study, so data from the original literature needed to be clearly described. Studies of high-quality design incorporating highly accurate research methods were selected for analysis. Inclusion criteria are: (1) single nucleotide polymorphism rs1800795 in IL-6 gene 174G/C position was assessed; (2) the final outcome was T2DM with or without microvascular complications; (3) the number of different genotypes and risk of complications respectively were provided; (4) clear presentation of units for data; (5) studies were obtained by means of standard formula.

Two investigators extracted the data independently, discrepancies were resolved by discussion.

2.3 Study subjects

Overall, 14 independent original articles (from 2000 onwards) including 4934 subjects and 9868 genetic locus were retrieved, based on relevant data on the effects of IL-6 gene promoter polymorphism (G/C) at position-174 variations (SNP rs1800795) on frequencies in complications of T2DM.

3. Meta-analysis Statistics

Meta-analysis and statistical analyses were conducted using the statistical software Stata 12.2. *P* values less than 0.05 were considered statistically significant. The chi-square test was utilized to assess the offset of frequencies of IL-6 polymorphisms from the expected values under the Hardy-Weinberg equilibrium (HWE) among T2DM patients with or without microvascular complications. Odds ratio (OR) was used as measure correlation between SNP rs1800795 in IL-6 gene 174G/C and risk of diabetic complications. The association between rs1800795 and the risk of diabetic complications was measured by the pooled OR with its corresponding 95% CI. We assessed the association between rs1800795 polymorphism and the susceptibility to complications of T2DM. The genetic models employed were exhibited as follows: the allelic genetic model (G vs. C), the homozygote genetic model (GG vs. CC), the heterozygote genetic model (GG vs. GC), the dominant genetic model (CC+CG vs. GG), and the recessive genetic model (CC vs. GG+GC) [7].

The statistical heterogeneity of the studies was calculated using the chi-square-based Q
test and I-squared index. If I-squared index was > 50% and P value was < 0.1, the study would be considered as significant heterogeneity, and in consequence the random-effected model would be used; On the contrary, if I-squared index was proved to be < 50% with the P value of > 0.1, the study would be considered as not of significant heterogeneity, and the fixed-effected model would be selected. To assess the impact of possible factors on pooled effect size and heterogeneity, subgroup analyses were performed.

Publication bias was assessed using the funnel plot method and Begg’s test, the level of P<0.05 was considered as statistically significant. Sensitivity analysis was conducted to test the influence of methodological quality by removing any low-quality studies from the meta-analysis. It was performed to determine the effect of each individual research on the pooled outcomes. As a measurement tool for investigation the quality of studies, ‘leave one out’ was used to evaluate the influence of the respective data on the integrated data by excluding one single data set from the pooled analyses one at a time.

Study quality was assessed using Newcastle-Ottawa Scale (NOS) ranging from a low of 0 to a high of 10 with the higher score representing higher quality. The cut-off values of NOS < or =5 suggested low-quality study while NOS >6 suggested high-quality study.

4. Result

Our study was intended to evaluate the relationship between the single nucleotide polymorphism rs1800795 in IL-6 gene 174G/C and the susceptibility of diabetic microvascular complications in T2DM.

4.1 Characteristics of eligible studies

We identified 20 databases from 14 studies with diabetic microvascular complications of T2DM including diabetic retinopathy, diabetic nephropathy, diabetic foot disease and diabetic neuropathy that met the inclusion criteria of this meta-analysis [8]. Figure 1 shows the flowchart of the study selection, by means of which 1701 articles were identified in the databases including 434 articles in Pubmed, 675 in SinoMed and 592 in Web of Science, respectively. Forty-one articles were assessed at full text level and 14 articles were included finally in this meta-analysis. These 14 articles included 2 low-quality studies and 12 high-quality studies (Table 1). The characteristics of articles included in this meta-analyses are listed in Table 1. The primary studies included in this meta-analyses were published between 2009 and 2019. There was no any effort to contact authors for relevant data, and the bibliographic search found no other relevant studies.
4.2 Findings from meta-analysis

The association between rs1800795 polymorphism in IL-6 gene and the susceptibility to diabetic microvascular complications of T2DM under five genetic models was assessed. We found that there was a lack of association between the risk of diabetic microvascular complications in T2DM and a homozygote genetic model (OR=1.071, 95% CI: 0.681-1.685, P=0.767), an allelic genetic model (OR=1.010, 95% CI: 0.959-1.063, P=0.703), a heterozygote genetic model (OR=1.107, 95% CI: 0.916-1.339, P=0.292), a dominant genetic model (OR=1.108, 95% CI: 0.885-1.387, P=0.372), and a recessive genetic model (OR=0.978, 95% CI: 0.646-1.478, P=0.917), respectively (Table 2, Figure 2).

In the subgroup analysis by types of diabetic microvascular complications, we also found that rs1000795 polymorphism was independent of the susceptibility of the four complications mentioned above in T2DM (P>0.05), both the homozygote genetic model and the allelic genetic model, with a homozygote genetic model (OR=0.952, 95% CI: 0.232-3.911, P=0.945) and an allelic genetic model (OR=1.009, 95% CI: 0.499-2.039, P=0.981) in diabetic retinopathy, a homozygote genetic model (OR=1.229, 95% CI: 0.939-1.607, P=0.133) and an allelic genetic model (OR=1.062, 95% CI: 0.881-1.282, P=0.527) in diabetic nephropathy, a homozygote genetic model (OR=0.230, 95% CI: 0.039-1.353, P=0.104) and an allelic genetic model (OR=0.808, 95% CI: 0.434-1.501, P=0.499) in diabetic foot disease, a homozygote genetic model (OR=0.825, 95% CI: 0.519-1.311, P=0.415) and an allelic genetic model (OR=0.919, 95% CI: 0.758-1.115, P=0.996) in diabetic neuropathy, respectively (Table 2, Figure 2).

4.3 Heterogeneity assessment

A significant between-study heterogeneity was found (I²=57.6-87.0%, p<0.01) (Table 2). We used subgroup analysis to find out the sources of heterogeneity through random-effects. The subgroup analysis by types of diabetic complications resulted to resolve the heterogeneity and the test of between-subgroup heterogeneity was significant (I²=77.0-83.2%, P<0.01) (Table 3).

4.4 Publication bias and Sensitivity analysis

Begg’s test was carried out to assess the potential publication bias in the present study and the result showed that significant publication bias was not observed (P>0.1). There were no asymmetries in funnel’s plots in the current analyses (Figure 2).

Sensitivity analysis was implemented to evaluate the results and overall meta-analysis
and subgroup analysis was performed for sensitivity analysis according to measurement tool. We found that all of the results remained relatively stable by excluding individual studies.

5. Discussion

As the prevalence of T2DM has risen to epidemic scale worldwide, diabetic complications have now become one of the most challenging health problems. The diabetic microvascular complications such as diabetic retinopathy, nephropathy, neuropathy or foot disease have always been the major dangerous outcomes of the disease, which contribute to disabilities and the high mortality rate in T2DM patients [1]. There is no diagnostic tool that can predict the high risk of developing diabetic microvascular complications before any damage is presented in a patient. In recent years, tests of genetic susceptibility to T2DM and its complications have been conducted. Genetic biomarkers as earlier predictable biomarkers may provide a new insight into the prediction and diagnosis of diabetic complications [9, 10].

Chronic low-grade activation of the immune system has been implicated in the pathogenesis of T2DM. Interleukin 6 (IL-6) has been established to play the role of inflammatory cytokine in the pathogenesis of T2DM. Dysregulation of IL-6 signaling and IL-6 itself has been implicated in the etiology of several autoimmune and inflammatory diseases including T2DM [11]. The elevated circulating level of IL-6 is an independent predictor of T2DM, patients with T2DM have significantly higher level of IL-6 compared than those without diabetes [12]. Studies have confirmed that IL-6 and its expression are associated with insulin resistance and beta-cell dysfunction, diabetic retinopathy and obstructive sleep apnea hypopnea syndrome (OSAHS) in T2DM [13-15]. However, IL-6 level in T2DM patients with diabetic microvascular complications is considered to be no higher than in patients without complications [16, 17].

SNP rs1800795 (-174G/C) of IL-6 gene in T2DM was first reported in 2003 showing that GG phenotype was a genetic determination of inflammation in the development of T2DM [18]. Significant sequence variation of IL-6 174G/C gene was widely distributed at varying frequencies in T2DM and healthy persons, this risk allele was also responsible for increased IL-6 serum level in genetically susceptible individuals [4]. However, the involvement of this SNP rs1800795 in diabetic complications in T2DM are unclear or controversial [5, 19]. In order to further conform the roles of IL-6 rs1800795 in the predication the risk of diabetic microvascular complications in T2DM, we conducted here a meta-analysis of eligible case-control studies, the association between rs1800795 polymorphism in IL-6 gene and risk
susceptibility to diabetic microvascular complications of T2DM under five genetic models was assessed.

Our results showed that there was no correlation between risk of diabetic microvascular complications in T2DM and a homozygote genetic model (OR=1.071, 95%CI: 0.681-1.685, P=0.767), an allelic genetic model (OR=1.010, 95% CI: 0.959-1.063, P=0.703), a heterozygote model (OR=1.107, 95% CI: 0.916-1.339, P=0.292), a dominant genetic model (OR=1.108, 95% CI: 0.885-1.387, P=0.372), and a recessive model (OR=0.978, 95% CI: 0.646-1.478, P=0.917), respectively. In the subgroup analysis by types of diabetic microvascular complications, we also found that rs1000795 polymorphism was independent of the susceptibility of the four complications mentioned above in T2DM patients (P>0.05), in both the homozygote genetic model and allelic genetic model. Our results were consistent with most other studies. The study of Rudofsky G et al [19] did not find any association between IL-6 -174G/C polymorphism and diabetic neuropathy or diabetic nephropathy in T2DM, which was supported by some other studies [16, 17, 20]. The study of Paine SK et al [9] indicated that the promoter polymorphism of IL-6 was not a potent risk factor for the pathogenesis of proliferative diabetic retinopathy. Other studies [10, 21] showed that there was no association between IL-6 -174G/C and diabetic foot disease risk in T2DM. However, there are contrary studies. Karadeniz M et al [22] evaluated the -174 G>C polymorphism of the IL-6 gene in T2DM with diabetic nephropathy in 43 cases of T2DM and 43 cases of T2DM with diabetic nephropathy and 340 healthy normal controls, the result of which showed that the frequency of the polymorphic G allele was 83.9% in diabetic patients with nephropathy versus 70.9% in those without nephropathy (p=0.039), the author suggested that the -174 G>C polymorphism of the IL-6 gene might be an independent risk factor for diabetic nephropathy in Turkish T2DM. The limitation of this study was that the sample was too small. The study of Chen B et al [7] indicated that IL-6 rs1800795, rs1800796 and rs1800797 might play important roles in diabetic nephropathy development while IL-6 rs2069837 and rs2069840 might not be related to diabetic nephropathy, but it is a pity that the data analyzed in this study included both T1DM and T2DM, and the results of T2DM were not analyzed separately. Libra M et al [23] also claimed that the GG genotype of IL-6 C-174G polymorphism might promote peripheral arterial disease development among individuals with T2DM by inducing increased release of IL-6 but without normal controls. Lu QK et al [24] concluded that IL-6 genotypes of rs1800795 GC and rs1800796 GG might point to a
relatively high risk for T2DM patients suffering from proliferative diabetic retinopathy in a Chinese population and which was associated with elevation of IL-6 expression in both mRNA and protein, but the sample was also too small (215 cases of T2DM with proliferative diabetic retinopathy and 207 cases of T2DM with a normal retinal function) and without normal controls. It was interesting that two studies showed that the -174G>C polymorphism may be associated with the risk of chronic renal failure [25,26]. It is a pity that we could not get data on renal function or analyze this phenomenon in our meta-analysis.

Numerous studies have provided clear evidence that IL-6 C-174G single nucleotide polymorphism was a risk factor in type 2 diabetes and contributed to higher serum interleukin-6 level among the participants [4,27,28]. We suggested that the SNP rs1800795 might be related to developing T2DM, but it might be of no major functional relevance in influencing the development and progression of diabetic microvascular complications. Furthermore, this could be due to different haplotypes with respect to other possible variants in the IL-6 promoter, which interfere with the promoter activity. Alternatively, sample size studied was insufficient to analyze associations of IL-6 polymorphism with diabetic microvascular complications. In addition, the target population we selected was T2DM patients. There may be significant differences in this SNP between T2DM patients and non-diabetic patients, but there is no significant difference among T2DM patients with or without complications in individuals. Finally, besides the IL-6 rs1800795, other SNPs of IL-6 such as rs1800796, rs1800797, rs1524107, rs2069837, rs2069840, etc. might also play important roles in the development of diabetic nephropathy or T2DM [7,16,29]. For example, Chang WT [16] suggested that IL-6 gene polymorphisms rs1800796 and rs1524107 might serve as predictors of progression of nephropathy in Chinese T2DM. This also needs further studies especially meta-analysis to prove.

Conclusion

In summary, comprehensive meta-analysis was performed and revealed no correlation between the SNP rs1000795 in IL-6 gene and diabetic microvascular complications in patients with T2DM. The results obtained in our study suggested that screening SNP rs1800795 may be helpless in identifying the high risk of developing diabetic microvascular complications in patients with T2DM. However, our findings still need to be confirmed by further large sample, multicenter and high-quality studies to provide theoretical basis. Our conclusion requires updated meta-analysis with a large sample size.
Limitations

Our review has some limitations that should be mentioned. Firstly, the methodological quality of the published literature should be noted, as only 12 of the 14 studies were categorized as high-quality ones (Table 1). Secondly, limited reference available for meta-analysis may lead to bias in the results. Thirdly, the target population we selected was T2DM patients, there may be significant differences in this SNP between T2DM patients and non-diabetic patients. Finally, some factors such as the small number of participants in some studies, could explain the heterogeneity in our results. These limitations reduced the reliability and strength of the conclusions. It is possible that these studies of our meta-analysis containing systematic biases may have confounded results.

Declaration of Competing Interest

The authors declare that they have no conflict of interests.

Funding

There was no funding support for this article.

Acknowledgments

We appreciate cooperation of all voluntaries participated in this study.

References

[1] Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035 [J]. Diabetes Res Clin Pract, 2014, 103(2): 137-149.

[2] Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030 [J]. PLoS Med, 2006, 3(11): e442.

[3] Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease [J]. Cytokine Growth Factor Rev, 2002, 13(4-5): 357-368.

[4] Nadeem A, Muntaz S, Naveed AK, et al. Association of IL-6 C-174G (rs 1800795) single nucleotide polymorphism with type 2 diabetes mellitus in Pakistani population [J]. J Pak Med Assoc, 2017, 67(3): 428-433.

[5] Mysliwska J, Zorea K, Mysiwiec M, et al. The -174GG interleukin-6 genotype is protective from retinopathy and nephropathy in juvenile onset type 1 diabetes mellitus [J]. Pediatr Res, 2009, 66(3): 341-345.
Ururahy MA, de Souza KS, Oliveira YM, et al. Association of polymorphisms in IL6 gene promoter region with type 1 diabetes and increased albumin-to-creatinine ratio [J]. Diabetes Metab Res Rev, 2015, 31(5): 500-506.

Chen B, Wu M, Zang C, et al. Association Between IL-6 Polymorphisms and Diabetic Nephropathy Risk: A Meta-analysis [J]. Am J Med Sci, 2019, 358(5): 363-373.

Henning RJ. Type-2 diabetes mellitus and cardiovascular disease [J]. Future cardiology, 2018, 14(6): 491-509.

Paine SK, Sen A, Choudhuri S, et al. Association of tumor necrosis factor alpha, interleukin 6, and interleukin 10 promoter polymorphism with proliferative diabetic retinopathy in type 2 diabetic subjects [J]. Retina, 2012, 32(6): 1197-1203.

Dhamodharan U, Viswanathan V, Krishnamoorthy E, et al. Genetic association of IL-6, TNF-alpha and SDF-1 polymorphisms with serum cytokine levels in diabetic foot ulcer [J]. Gene, 2015, 565(1): 62-67.

Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes [J]. Inflammopharmacology, 2018, 26(3): 685-698.

Wu W, Wang M, Sun Z, et al. The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes [J]. Acta Diabetol, 2012, 49(1): 3-7.

Yoshida S, Kubo Y, Kobayashi Y, et al. Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedema [J]. Br J Ophthalmol, 2015, 99(7): 960-966.

Hui P, Jia S, Ma W, et al. The changes and significance of IL-6 levels in patients with OSAHS associated Type 2 diabetes Mellites [J]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2015, 29(19): 1726-1728.

Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells [J]. Nat Med, 2011, 17(11): 1481-1489.

Chang WT, Huang MC, Chung HF, et al. Interleukin-6 gene polymorphisms correlate with the progression of nephropathy in Chinese patients with type 2 diabetes: A prospective cohort study [J]. Diabetes Res Clin Pract, 2016, 120(15-23).

Fathy SA, Mohamed MR, Ali MAM, et al. Influence of IL-6, IL-10, IFN-gamma and...
TNF-alpha genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients [J]. Biomarkers, 2019, 24(1): 43-55.

Vozarova B, Fernandez-Real JM, Knowler WC, et al. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians [J]. Hum Genet, 2003, 112(4): 409-413.

Rudofsky G, Jr., Schlotterer A, Reismann P, et al. The -174G>C IL-6 gene promoter polymorphism and diabetic microvascular complications [J]. Horm Metab Res, 2009, 41(4): 308-313.

Abrahamian H, Endler G, Exner M, et al. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines [J]. Exp Clin Endocrinol Diabetes, 2007, 115(1): 38-41.

Erdogan M, Kulaksizoglu M, Solmaz S, et al. The relationship of Interleukin-6 -174 G>C gene polymorphism in type 2 diabetic patients with and without diabetic foot ulcers in Turkish population [J]. Foot (Edinb), 2017, 30(27-31).

Karadeniz M, Erdogan M, Berdeli A, et al. Association of interleukin-6 -174 G>C promoter polymorphism with increased risk of type 2 diabetes mellitus patients with diabetic nephropathy in Turkey [J]. Genet Test Mol Biomarkers, 2014, 18(1): 62-65.

Libra M, Signorelli SS, Bevelacqua Y, et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease [J]. J Clin Pathol, 2006, 59(2): 211-215.

Lu QK, Zhang JT, Zhao N, et al. Association of IL-6 Gene (-174 and -572 G/C) Polymorphisms with Proliferative Diabetic Retinopathy of Type 2 Diabetes in a Chinese Population [J]. Ophthalmic Res, 2017, 58(3): 162-167.

Ng DP, Nurbaya S, Ye SH, et al. An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients [J]. Kidney Int, 2008, 74(4): 521-527.

Neelofar K, Ahmad J, Ahmad A, et al. Study of IL4-590C/T and IL6-174G/C Gene Polymorphisms in Type 2 Diabetic Patients With Chronic Kidney Disease in North Indian Population [J]. J Cell Biochem, 2017, 118(7): 1803-1809.

Kubaszek A, Pihlajamaki J, Komarovsky V, et al. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired
glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study [J]. Diabetes, 2003, 52(7): 1872-1876.

[28] Saxena M, Agrawal CG, Srivastava N, et al. Interleukin-6 (IL-6)-597 A/G (rs1800797) & -174 G/C (rs1800795) gene polymorphisms in type 2 diabetes [J]. Indian J Med Res, 2014, 140(1): 60-68.

[29] Zambrano-Galvan G, Reyes-Romero MA, Lazalde B, et al. Risk of microalbuminuria in relatives of subjects with diabetic nephropathy: a predictive model based on multivariable dimensionality reduction approach [J]. Clin Nephrol, 2015, 83(2): 86-92.

[30] Papaoikonomou S, Tousoulis D, Tentolouris N, et al. Assessment of the effects of 174G/C polymorphism on interleukin 6 gene on macrovascular complications in patients with type 2 diabetes mellitus [J]. Int J Cardiol, 2014, 172(1): e190-191.

[31] Hameed I, Masoodi SR, Malik PA, et al. Genetic variations in key inflammatory cytokines exacerbates the risk of diabetic nephropathy by influencing the gene expression [J]. Gene, 2018, 661: 51-59.

### Table1. Characteristics of including studies

| Study | Author | Ethnicity | Year | Case/control | M/F | NOS | Complications |
|-------|--------|-----------|------|--------------|-----|-----|---------------|
| 1     | Rudofsky[19] | Germany | 2009 | 216/282 | /   | 5   | Diabetic retinopathy, nephropathy and foot disease |
| 2     | Paine[9]  | India    | 2012 | 253/340 | 261/232 | 6   | Diabetic retinopathy |
| 3     | Dhamadhuran[10] | India | 2015 | 270/139 | 261/148 | 7   | Diabetic retinopathy, neuropathy and foot disease |
| 4     | Lu[24]   | Han      | 2017 | 215/207 | /   | 7   | Diabetic retinopathy |
| 5     | Erdogan[21] | Turkey   | 2017 | 50/35 | 42/43 | 6   | Diabetic retinopathy, neuropathy and foot disease |
| 6     | Abrahamian[20] | Austria | 2007 | 66/75 | /   | 7   | Diabetic nephropathy |
| 7     | Ng[25]   | America  | 2008 | 294/168 | /   | 9   | Diabetic nephropathy |
| 8     | Karadeniz[22] | Turkey | 2014 | 43/43 | /   | 6   | Diabetic nephropathy |
| 9     | Zambrano-Galvan[29] | Mexico | 2015 | 70/60 | /   | 6   | Diabetic nephropathy |
| 10    | Chang[16] | Taiwan   | 2016 | 143/424 | 269/298 | 9   | Diabetic nephropathy |
| 11    | Neelofar[26] | Indian  | 2017 | 50/50 | /   | 8   | Diabetic nephropathy |
|   | Study Selection Flowchart | Articles identified through database search (n=1701) | Pubmed (n=434) | SinoMed (n=675) | Web of Science (n=592) | Records excluded because of duplicates (n=364) and irrelevant topics (n=1296) | Full text articles assessed for eligibility (n=41) | Records excluded because of other reasons (n=27) | Studies included (n =14) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | | | | | | | | | |
| 2 | | | | | | | | | |

**Figure 1.** Study selection flowchart

**Table 2.** Overall analysis between genotypes and allele frequency with complications of T2DM

| Genetic Model | Case (n) | Control (n) | P (value) | OR (95% CI) | I² (%) | P for heterogeneity |
|---------------|----------|-------------|-----------|-------------|-------|-------------------|
| G vs. C       | G 4147   | 5599        | 0.703     | 1.010       | 87.0  | <0.010            |
|               | C 1601   | 2315        |           | (0.959-1.063) |       |                   |
| GG vs. CC     | GG 1548  | 2096        | 0.767     | 1.071       | 77.0  | <0.010            |
|               | CC 278   | 477         |           | (0.681-1.685) |       |                   |
| GG vs. GC     | GG 1548  | 2096        | 0.292     | 1.107       | 57.6  | <0.010            |
|               | GC 1045  | 1427        |           | (0.916-1.339) |       |                   |
| CC+CG vs. GG  | CC+CG 1323 | 1904       | 0.372     | 1.108       | 73.5  | <0.010            |
|               | GG 1548  | 2096        |           | (0.885-1.387) |       |                   |
| Complication | Genetic Model | Case (n) | Control (n) | P (value) | OR (95% CI) | \( I^2 \) (%) | P for heterogeneity |
|--------------|---------------|----------|-------------|-----------|-------------|---------------|------------------|
| Diabetic     | GG vs. CC     | GG       | 352         | 0.945     | 0.952       | (0.232-3.911) | 92.5            | <0.010            |
|              |               | CC       | 83          |           |             |               |                  |                  |
| Retinopathy  | G vs. C       | G        | 959         | 0.981     | 1.009       | (0.499-2.039) | 94.7            | <0.010            |
|              |               | C        | 421         |           |             |               |                  |                  |
| Diabetic     | GG vs. CC     | GG       | 673         | 0.133     | 1.229       | (0.939-1.607) | 0.0             | 0.944            |
|              |               | CC       | 337         |           |             |               |                  |                  |
| Nephropathy  | G vs. C       | G        | 1683        | 0.527     | 1.062       | (0.881-2.182) | 48.2            | 0.043             |
|              |               | C        | 525         |           |             |               |                  |                  |
| Diabetic     | GG vs. CC     | GG       | 125         | 0.104     | 0.230       | 0.0           | 0.944            |
|                | CC  |    |     |       |       |       |
|----------------|-----|----|-----|-------|-------|-------|
|                | G vs. C | G  |    |     |       |       |
| Foot Disease   |     | 359| 164 | 0.499 | 0.808 | 57.5  |
|                |     | 123| 64  |       |       | 0.125 |
|                |     |    |     | (0.434-1.501) |       |
| Diabetic       |     | GG |    |     |       |       |
|                |     | 230| 315 | 0.415 | 0.825 | 0.0   |
|                |     | 41 | 62  |       |       | 0.427 |
|                |     | (0.519-1.311) |       |
| Neuropathy     |     | G  |    |     |       |       |
|                |     | 666| 868 | 0.996 | 0.919 | 0.0   |
|                |     | 288| 402 |       |       | 0.458 |
|                |     | (0.758-1.115) |       |

Table 3. Subgroup analysis of genotypes and allele frequency with complications of T2DM.
Figure 2 Forest plot for meta-analysis of association between IL-6 -174G/C polymorphism with risk of complications in type 2 diabetes in subgroup analysis. Begg’s funnel plot showing
the publication bias and results of sensitivity analysis showing by measurement tool of leave one out in subgroup analysis.
